E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Exclusion Criteria

• •1. History of erosive esophagitis verified by endoscopy.
• •2. History of gastroesophageal reflux disease (GERD) diagnosed by a physician.
• •3. Patients who have a history of Barrett's esophagus or esophageal stricture.
• •4. Evidence of any medical condition that may interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
• •5. Patients who require continuous use of proton pump inhibitors, histamine receptor (H2) blockers, or prokinetics. Prior intermittent use of these agents is permitted if they are discontinued at least three days prior to the run-in phase. The H2 blocker, cimetidine (Tagamet®), must be discontinued for at least seven days before the study drug is administered.